Akebia Therapeutics, Inc. (AKBA): Cost of Revenue
$39.46M
Year ended 2025-12-31
$44.63M
Trailing 12 months to 2026-06-30
-22.7%
3-year compound annual growth
-33.2%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.46M | -37.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $63.18M | -14.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $74.15M | -13.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $85.57M | -43.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $150.67M | -49.2% | 2023-08-28, From 2021-01-01 |
| 2020-12-31 | $296.48M | +104.0% | 2023-08-28, From 2020-01-01 |
| 2019-12-31 | $145.34M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $7.77M | n/a | 2021-02-25, From 2018-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $39.46M | -37.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $58.16M | -9.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $113.25M | +50.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $67.93M | +38.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $19.49M | +45.8% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $40.97M | -8.7% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
Compare AKBA, PBYI, SDGR, HROW side by side · Screen every company in Pharmaceutical Preparations ↗